AstraZeneca Investor Day Presentation Deck
T-DXd transforms the treatment paradigm
for patients with metastatic HER2+ breast cancer
18
Second-line monotherapy data
that rivals first-line current
standard triplet therapy
Consistency across all sub-groups
Improved safety profile
1L
1L
2L
2L+
3L+
Trastuzumab + pertuzumab + taxane,
CLEOPATRA¹: mPFS = 18.7 months
T-DM1 + pertuzumab,
MARIANNE²: mPFS = 15.2 months
T-DXd
DESTINY-Breast03³: mPFS = not yet reached
Investigator-assessed PFS: 25.1 months
T-DM1, EMILIA4:
mPFS = 9.6 months
T-DXd
DESTINY-Breast015: mPFS = 19.4 months
1. Swain SM, Baselga J et al. N Engl J Med. 2015;372:724-34. 2. Perez J et al. Expert Opin Biol Ther. 2021;21:811-24 3. Cortés, J, Presented at ESMO 2021, Abstract LBA1 on 18 September 2021. 4. Verma S et al. N Engl J Med. 2012;367:1783-91 5. DB01: Modi S et al.
Presented at San Antonio Breast Cancer Symposium. 2020. Poster PD3-06.View entire presentation